Skip to main content

Advertisement

Table 1 Characteristics of studies included for meta-analysis

From: The prognostic impact of decreased pretreatment haemoglobin level on the survival of patients with lung cancer: a systematic review and meta-analysis

Author Year Country Subtype Tumor stage Sample size Median Age(years) Gender (M/F) Treatment modality Follow up (months) Survival analysis Cut-off value (g/dl) Analysis Qualitya
Osterlind, K [21] 1986 Denmark SCLC NR 778 NR NR Chemoradiotherapy NR OS 12 MV 6
Albain, K S [22] 1991 USA NSCLC NR 1925 NR 77%/23% Chemotherapy NR OS 11 MV 5
Takigawa, N [23] 1996 Japan NSCLC Advanced 186 68 134/51 Chemoradiotherapy NR OS 11 MV 7
Wigren, T [24] 1997 Finland NSCLC Mix 502 65 459/43 Radiotherapy 48 OS 12.5 MV 6
Ohlhauser, C [25] 1997 Germany NSCLC Mix 456 65.5 391/65 Radiotherapy NR OS 12.7 MV 6
Jazieh, A R [26] 2000 USA NSCLC Early 454 67 410/44 Surgery 28 OS,EFS 10 MV 5
Rzyman, W [27] 2003 Poland NSCLC Mix 493 59.7 493/100 Surgery NR OS 12 MV 5
Bremnes, R M [28] 2003 Norway SCLC Limited: 214
Extensive: 222
436 64 280/156 Chemoradiotherapy >60 OS Male: 13
Female: 11.5
MV 5
Langendijk, H [29] 2003 Netherland NSCLC Mix 529 68 87%/13% Radiotherapy >24 OS Continuous MV 6
Tammemagi, C M [30] 2003 USA LC NR NR NR NR Mix 29.7 OS NR MV 5
Yovino, S [31] 2005 USA NSCLC Early 82 68 48/34 Surgery 20.8 OS,RFS 12 MV 7
Berardi, R [32] 2005 Italy NSCLC Mix 439 68 374/65 Surgery 27 OS 10 MV 7
Pradier, O [33] 2005 Germany NSCLC Advanced 56 NR 44/12 Radiotherapy NR OS 11.6 UV 7
Aoe, K [34] 2005 Japan LC Mix 611 64 482/129 NR NR OS Male: 13
Female: 12
MV 7
Mohan, A [35] 2006 India SCLC Limited: 27.6%
Extensive: 72.4%
76 54.9 84.2%/5.8% Chemoradiotherapy NR OS 12.8 MV 5
Mandrekar, S J [36] 2006 USA NSCLC Advanced 1053 63.3 NR NR NR OS, TTP Male: 13.2
Female: 11.5
MV 5
Laurie, SA [37] 2006 Canada SCLC Limited 130 62 63/67 Chemoradiotherapy NR OS, PFS 10 MV 6
Paul, I [38] 2006 UK NSCLC Mix 42 68.1 35/7 Surgery 55.2 OS Continuous MV 6
Gauthier, I [39] 2007 Canada NSCLC Early 476 61.3 311/165 Chemotherapy Surgery NR OS 12 MV 5
Ademuyiwa, F O [40] 2007 India & USA NSCLC Advanced 2013 NR 134/69 Chemoradiotherapy 25.6 OS Continuous MV 6
Panagopoulos, ND [41] 2008 Greece NSCLC Mix 331 64 295/36 Surgery 27.2 OS 12 MV 7
Park, M J [42] 2008 Korean NSCLC NR 358 NR NR Chemotherapy NR OS 10 MV 5
Jacot, W [43] 2008 France NSCLC Mix 301 63 242/59 Mix 20.8 OS 11 MV 6
Florescu, M [44] 2008 Canada NSCLC Advanced 485 NR 313/72 Chemotherapy NR OS Male: 13.6
Female: 12
MV 5
Stinchcombe, T E [45] 2009 USA NSCLC Advanced 331 NR 218/113 Chemoradiotherapy 88 OS 13 MV 6
Garrido, P [13] 2009 Spain NSCLC Advanced 139 NR 127/12 Chemoradiotherapy 23 OS 12 MV 6
Belbaraka, R [46] 2010 France NSCLC Advanced 45 58.5 30/15 Chemotherapy NR OS Male: 11.5
Female: 13
MV 7
Qiu MZ [47] 2010 China NSCLC Mix 430 59 310/120 Mix 31 OS 11 UV 6
Ovcaricek, T [48] 2010 Slovenia NSCLC Mix 53 65 40/13 Chemotherapy NR PFS Continuous MV 6
Yi, S Y [49] 2011 Korea NSCLC Advanced 191 72 NR Chemotherapy NR OS 12 MV 6
Castro, J G [50] 2011 Brazil NSCLC Advanced 142 63 95/47 Chemotherapy NR OS 12 UV 5
Kishida, Y [14] 2011 Japan NSCLC Advanced 86 65 72/14 Chemoradiotherapy 20 OS 12 UV 7
Janku, F [51] 2011 USA NSCLC Mix 85 62 51/34 Chemotherapy+ targeted NR OS 12 UV 5
Gioulbasanis, I [52] 2011 Greece LC NR 115 66 101/14 Chemotherapy 38.2 OS Continuous UV 7
Hsu C L [53] 2012 China NSCLC Advanced 144 39.1 70/74 Chemoradiotherapy NR OS 11 MV 6
Holgersson G [54] 2012 Sweden NSCLC Mix 833 NR NR Mix NR OS 11 MV 5
Ng T [55] 2012 USA NSCLC Early 361 NR 161/200 Surgery 48 OS, DFS Male: 13
Female: 12
MV 7
Wu, C [56] 2012 China SCLC Extensive 200 NR 174/26 Chemoradiotherapy NR OS NR MV 6
Kiely, B E [57] 2013 Australia NSCLC Advanced 244 64 146/98 Chemotherapy 21 OS 12 UV 5
Tas, F [58] 2013 Turkey LC Mix 100 59 91/9 Chemotherapy 5 OS 12 UV 5
Qu, X [59] 2014 China NSCLC Mix 649 58.9 456/193 Surgery 43 OS, RFS 14.6 MV 6
Smith, M O [60] 2014 UK NSCLC Mix 563 68.5 305/258 Surgery NR OS 13.1 MV 5
Kacan, T [61] 2014 Turkey NSCLC Mix 299 61 270/29 Mix NR OS 12 MV 5
Strouse, C S [12] 2014 USA NSCLC Advanced 2845 NR NR Chemotherapy NR OS NR MV 5
Oguz, A [62] 2014 Turkey NSCLC Advanced 186 63 161/25 NR NR OS Continuous MV 5
Crvenkova, S [63] 2015 Republic of Macedonia NSCLC Advanced 85 58.2 75/10 Chemoradiotherapy 36 OS 12 UV 6
Wu, X Y [64] 2015 China NSCLC Advanced 186 NR NR Chemoradiotherapy >36 OS 12 UV 6
Imai, H [65] 2015 Japan NSCLC Advanced 159 64 126/33 Radiotherapy NR OS Continuous MV 5
Xie, D [66] 2015 China SCLC Limited:555
Extensive: 383
938 68 500/438 Mix 10.8 OS 12 MV 6
Abazari M [67] 2015 Iran LC Mix 355 63.5 256/99 Mix NR OS 14 UV 5
Cata, J P [68] 2016 USA NSCLC Early 861 65.29 394/467 Surgery 108.28 OS, RFS Male: 13
Female: 12
MV 6
Shaverdian, N [69] 2016 USA NSCLC Early 110 76 NR radiotherapy 28.9 OS,DFS 12 MV 5
Lin, Y [11] 2016 China NSCLC Mix 69 56 54/15 Mix NR OS,DFS Male: 12
Female: 11
MV 6
Park S [70] 2016 Korea NSCLC Mix 630 64 236/394 Chemotherapy NR OS, PFS Male: 13
Female: 12
UV 5
Shaverdian, N [69] 2016 USA NSCLC Early 147 NR NR Radiotherapy 28.9 OS, DFS Continuous MV 6
Minami, S [71] 2016 Japan NSCLC Advanced 103 69.5 85/18 Chemotherapy NR OS Continuous MV 6
Lee S [72] 2017 Korea NSCLC Advanced 135 NR 78/57 Korean medicine NR OS Male: 13
Female: 12
UV 5
  1. Abbreviations: NSCLC non-small cell lung cancer, SCLC small cell lung cancer, LC lung cancer, M/F male/female, NR not reported, OS overall survival, DFS disease-free survival, RFS relapse-free survival, PFS progression-free survival, EFS event-free survival, TTP time to progression, MV multivariate, UV univariate
  2. aThe quality of studies was assessed by Newcastle-Ottawa scale